Navigation Links
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
Date:12/6/2008

ansfusions were the same in both arms.

Oral Eltrombopag for the Long-Term Treatment of Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP): Results of a Phase III, Double-Blind, Placebo-Controlled Study

[Abstract #400]

Gregory Cheng, ChineseUniversityof Hong Kong,Hong Kong,China

This double-blind, multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significantly increased platelet counts, decreased bleeding symptoms, allowed for a reduction of baseline ITP therapy, and reduced the use of rescue medications in previously treated patients with chronic ITP. In chronic ITP, low blood platelet counts persist unless treated and can last for an indefinite amount of time.

A total of 197 patients with platelet counts less than 30,000 microliters were stratified by splenectomy status, use of baseline ITP medication, and platelets of less than or equal to 15,000 microliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patients) or placebo once daily (62 patients). Depending on individual platelet response, the dose of eltrombopag could be titrated within a range from 25 mg once daily to a maximum dose of 75 mg once daily.

The primary endpoint of the study was the odds of achieving platelet counts between 50,000 and 400,000 microliters in patients receiving eltrombopag as compared with placebo. To measure the drug's safety, bleeding symptoms were prospectively evaluated using the WHO Bleeding Scale.

Patients who received eltrombopag were eight times more likely to achieve platelet counts of 50,000 to 400,000 microliters during the six-month treatment period as compared with those in the placebo arm. While baseline median platelet counts were 16,000 microliters in both
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Jan. 14, 2014 InformEx, North America,s ... high-value chemistry, will hold the 30 th edition of ... Convention Center from January 21-24. (Logo: ... top pharmaceutical, fine chemical and specialty chemical companies will take ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) ... offering of 21,250,000 shares of its common stock and warrants ... of approximately $17.0 million.  The securities sold in the offering ... a warrant to purchase 0.5 of a share at a ...
... 16, 2011 The federal government,s tracking system for ... to account for a new procurement policy implemented last ... higher number of power wheelchairs provided than were actually ... and manufacturers report declines of 30 percent or more ...
Cached Medicine Technology:ADVENTRX Announces Closing of Public Offering 2ADVENTRX Announces Closing of Public Offering 3American Association for Homecare: CMS Inexcusably Releases Flawed Utilization Data 2American Association for Homecare: CMS Inexcusably Releases Flawed Utilization Data 3American Association for Homecare: CMS Inexcusably Releases Flawed Utilization Data 4
(Date:7/9/2014)... 2014 For the first time, researchers have access ... in Canada uses health care. A new study, called ... demonstrate the unique challenges faced by urban Aboriginal people ... Hospital. , The findings, published today in ... Nations individuals and the general population. , Researchers interviewed ...
(Date:7/9/2014)... an innovative tool that captures heretofore hidden ways that ... a protein that makes breast cancer cells more likely ... trigger cancer,s spread in part by blocking two other ... that suggests these two disease processes could have unexpected ... July 10 issue of Nature , points to ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... (July 8, 2014) Researchers from Montefiore Medical ... Medicine of Yeshiva University will present new findings ... July 12 July 17 in Copenhagen, Denmark. Data ... could prompt transition from cognitive normality to mild cognitive ... Einstein Aging Study , established in 1980 to ...
(Date:7/9/2014)... one of the most important organs in the human ... our food properly this is its synthesis function ... organism this is its detoxification function. Lack of ... all damage the liver. The resulting diseased cells can ... life-threatening liver failure. According to the German Liver Foundation, ...
Breaking Medicine News(10 mins):Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... influenced by advertisements that show horrific consequences of drink-driving ... report . ,The UK Department of ... drink-driving can influence young men not to sit behind ... show that a minimum penalty of a one-year driving ...
... David Beckham has admitted that he is a big softie who ... recently moved to the US after joining LA Galaxy, said that ... while he is watching an upsetting scene in the film. ... we'll be watching a film that's not even upsetting and Victoria ...
... study has suggested that teens indulgence in non-suicidal ... suspected. ,Non-suicidal self-injury is the deliberate, ... intent. ,The findings are important because ... adolescents in the general population than previously thought, ...
... to gain approval from the Food and Drug Administration (FDA), ... Wilson Guthrie, a 61-year-old man from Kansas, suffering from ... home, with that experimental heart-assist device that keeps his heart ... the cardiothoracic ICU has had, and that a lot of ...
... last year in Sierra Leone's capital Freetown last year has ... ,A senior health worker attributed the fall in rabies cases ... Doctors at the main referral Connaught Hospital are worried about ... ,The hospital has had to rely heavily on ...
... who are not graduates of recognised foreign medical schools, ... to practise in Singapore starting next year, the ... from countries like the Philippines, India and Myanmar, have ... Medical Council has allowed institutions to hire them since ...
Cached Medicine News:Health News:Drink-drivers Not Influenced by Ads Unless It Affects Them Personally 2Health News:Self-harming Among Teens More Common Than Thought 2Health News:Self-harming Among Teens More Common Than Thought 3Health News:US Patient Implanted With HeartMate II, Leaves ICU 2
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Micro Blade tip 6900 style, straight. Dimensions: 15.2 mm x 2.5 mm x 6.2 mm....
Needle Knife, straight, full handle, non-reflective, 0.74 mm width....
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled bevel up. Blade tip dimension: 14.4 mm x 3.2 mm x 3.7 mm....
Medicine Products: